Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma ...Middle East

STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell...

Hence then, the article about zynlonta loncastuximab tesirine approved in the eu for the treatment of relapsed or refractory diffuse large b cell lymphoma was published today ( Wednesday 21/12/2022 - 12:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma )

Also on site :

• Cuban official accuses US of ‘piracy’ against sanctioned Caribbean island
• EU must stop funding Kiev after Zelensky’s ‘insults’ – Italian MP
• The One Florida Hotel Family Travel Advisors Book on Repeat—and It’s Not Disney